141940-29-6

Basic information

• Product Name: N-BOC-5-TRIFLUOROMETHYLANTHRANILIC ACID
• Synonyms: N-BOC-5-TRIFLUOROMETHYLANTHRANILIC ACID;Benzoic acid, 2-[[(1,1-diMethylethoxy)carbonyl]aMino]-5-(trifluoroMethyl)-;2-(tert-butoxycarbonyl)-5-(trifluoroMethyl)benzoic acid;2-tert-Butoxycarbonylamino-5-trifluoromethyl-benzoic acid
• CAS NO: 141940-29-6
• Molecular Formula: C₁₃H₁₄F₃NO₄
• Molecular Weight: 305.25
• Mol File: 141940-29-6.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: N-BOC-5-TRIFLUOROMETHYLANTHRANILIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: N-BOC-5-TRIFLUOROMETHYLANTHRANILIC ACID(141940-29-6)
• EPA Substance Registry System: N-BOC-5-TRIFLUOROMETHYLANTHRANILIC ACID(141940-29-6)

Safety Data

• Hazardous Substances Data: 141940-29-6(Hazardous Substances Data)

Usage

General Description

N-BOC-5-trifluoromethylanthranilic acid is a chemical compound that belongs to the class of anthranilic acids. It is commonly used as a building block in organic synthesis, specifically in the synthesis of pharmaceutical compounds. The "N-BOC" in its name refers to the tert-butoxycarbonyl protective group attached to the nitrogen atom, which helps to control the reactivity of the molecule. The trifluoromethyl group attached to the aromatic ring makes this compound useful in medicinal chemistry for the development of drugs with improved pharmacokinetic properties. Overall, N-BOC-5-trifluoromethylanthranilic acid is a versatile chemical with uses in drug discovery and organic synthesis.

Upstream product

• 124-38-9 carbon dioxide 
• 141940-37-6 tert-butyl (4-(trifluoromethyl)phenyl)carbamate 
• 455-14-1 4-trifluoromethylphenylamine 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 439150-97-7 (2-tert-Butoxycarbonylamino-5-trifluoromethyl-benzoylamino)-acetic acid 
• 439151-92-5 2-(3-isopropyl-ureido)-5-trifluoromethyl-benzoic acid 
• 781-94-2 6-(trifluoromethyl)-2H-benzo[d][1,3]oxazine-2,4(1H)-dione 
• 746670-23-5 C₃₁H₃₇F₃N₄O₆ 
• 1246522-41-7 tert-butyl 2-[({(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}amino)carbonyl]-4-(trifluoromethyl)phenylcarbamate 
• 1119086-06-4 2-(6-(3-ethoxyphenyl)-5-methylpyridin-3-ylamino)-5-(trifluoromethyl)benzoic acid 
• 1108668-05-8 2-amino-5-trifluoromethylbenzoic acid ethyl ester 
• 445480-25-1 2-(Iso-propoxycarbonyl)amino-5-trifluoromethylbenzoic acid 
• 83265-53-6 2-amino-5-(trifluoromethyl)benzoic acid 
• 1176145-50-8 C₁₆H₁₈F₃NO₄ 
• 845797-42-4 2-amino-5-(trifluoromethyl)benzoic acid, hydrochloride 

Relevant articles and documents

AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS

New azabiphenylaminobenzoic acid derivatives having the chemcial structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of the dehydroorotate dihydrogenase (DHODH)

Bacterial translation inhibitors, 1-acylindazol-3-ols as anthranilic acid mimics

The discovery and initial optimization of a novel anthranilic acid derived class of antibacterial agents has been described in a recent series of papers. This paper describes the discovery of 1-acylindazol-3-ols as a novel bioisostere of an anthranilic acid. The synthesis and structure-activity relationships of the indazol bioisosteres are described herein.

Synthesis and Biological Evaluation of New 1,2-Dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for Treatment of Autoimmune Disorders: Structure-Activity Relationship

Roquinimex-related 3-quinolinecarboxamide derivatives were prepared and evaluated for treatment of autoimmune disorders. The compounds were tested in mice for their inhibitory effects on disease development in the acute experimental autoimmune encephalomyelitis model and selected compounds in the beagle dog for induction of proinflammatory reaction. Structure-activity relationships are discussed. Compound 8c, laquinimod, showed improved potency and superior toxicological profile compared to the lead compound roquinimex (1b, Linomide) and was selected for clinical studies (currently in phase II).